Paul J. Hastings

Mr. Hastings is a distinguished leader in the biopharmaceutical industry and currently serves as Chief Executive Officer and Board Member of engineered cell therapy company Nkarta since 2018. He is also a current Director of EnGene, a non-viral gene therapy company, and recently served as the Chair of the Biotechnology Innovation Organization (BIO). Over his career, he has held numerous top leadership roles, including CEO of OncoMed, QLT, Axys Pharmaceuticals, and LXR Biotechnology, and President of Chiron BioPharmaceuticals. He has guided corporate strategy as Chair of Pacira Biosciences, Proteon Therapeutics and Proteolix, and as a Director of ViaCyte, Relypsa and ViaCell, and previously held leadership roles in global biotechnology companies as President of Genzyme Therapeutics Europe and Genzyme Global Therapeutics, as well as progressive executive roles at Hoffmann-La Roche. A committed mentor and patient advocate, he co-founded and chairs the board of Youth Rally Inc. and serves on the Board of the Termeer Foundation.